de Lange D W, Fijnheer R, Wittebol S
Universitair Medisch Centrum, afd. Interne Geneeskunde, F02.107, Heidelberglaan 100, 3508 GA Utrecht.
Ned Tijdschr Geneeskd. 2003 Sep 13;147(37):1808-11.
Two patients, a man aged 69 and a woman aged 64, were diagnosed with Von-Willebrand syndrome caused by monoclonal gammopathy. The man, who was admitted for hip surgery, had a history of long episodes of epistaxis. The patient was treated with immunoglobulin and the hip operation was carried out with no complications. The woman suffered from haemorrhagic diathesis. She was advised that should she undergo an invasive procedure then treatment with a prophylactic with intravenous immunoglobulin or Von-Willebrand factor (VWF)/factor-VIII-concentrates must be administered. Acquired Von-Willebrand syndrome is a rare condition with an estimated prevalence of 0.04-0.13%. It is linked to a large number of underlying diseases such as paraproteinaemia, multiple myeloma (Kahler's disease), myeloproliferative disease, lymphoproliferative disease, auto-immune disease, solid tumours and hypothyroidism. Recognition depends on a careful case-history and identification of the underlying disease. For its diagnosis VWF antigen. VWF propeptide, activated partial thromboplastin time and factor VIII are of importance. Technically, it is difficult to show the presence of VWF antibodies as it concerns a heterogeneous group of antibodies. There are two pillars of treatment: symptomatic treatment of the bleeding tendencies using desmopressin, VWF-concentrate or intravenous gammaglobulin, and treatment of the underlying disease. The latter form of treatment can lead to acquired Von-Willebrand-syndrome disappearing altogether.
两名患者,一名69岁男性和一名64岁女性,被诊断患有由单克隆丙种球蛋白病引起的血管性血友病。该男性因髋关节手术入院,有长期鼻出血病史。患者接受了免疫球蛋白治疗,髋关节手术顺利,未出现并发症。该女性患有出血素质。她被告知,如果她接受侵入性手术,那么必须给予静脉注射免疫球蛋白或血管性血友病因子(VWF)/凝血因子VIII浓缩物进行预防性治疗。获得性血管性血友病综合征是一种罕见疾病,估计患病率为0.04 - 0.13%。它与大量潜在疾病有关,如副蛋白血症、多发性骨髓瘤(卡勒病)、骨髓增殖性疾病、淋巴增殖性疾病、自身免疫性疾病、实体瘤和甲状腺功能减退症。诊断依赖于仔细的病史询问和潜在疾病的识别。对于其诊断,VWF抗原、VWF前肽、活化部分凝血活酶时间和凝血因子VIII很重要。从技术上讲,由于涉及一组异质性抗体,很难检测到VWF抗体的存在。治疗有两大支柱:使用去氨加压素、VWF浓缩物或静脉注射丙种球蛋白对出血倾向进行对症治疗,以及对潜在疾病进行治疗。后一种治疗形式可导致获得性血管性血友病综合征完全消失。